Synlogic (SYBX)
OTHER OTC:SYBX
Want to see SYBX full AI Analyst Report?
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$8.77M
Enterprise Value-$6.15M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,641
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap-0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtZero reported debt materially reduces fixed financing costs and lowers structural insolvency risk. Over a multi-month horizon this increases strategic optionality for funding R&D, executing partnerships, or raising capital on better terms, improving the company's financial flexibility.
Markedly Lower Cash BurnA materially reduced operating cash outflow versus prior years extends runway and lowers near-term financing pressure. Sustained lower burn allows management to prioritize clinical programs or partnerships, making execution risk more manageable over the next several months.
Platform-level Product OptionalityA proprietary engineered-microbe platform creates durable competitive potential and program diversification across metabolic and immuno-oncology indications. Platform-driven pipelines support partnership and licensing opportunities that can generate non-dilutive funding and long-term value creation.
Bears Say
Near-zero Recurring RevenueAbsent product sales, the company depends on collaboration, milestone, or grant revenues that are irregular. This lack of recurring revenue creates lasting funding volatility and forces reliance on external financing or partner deals to sustain R&D and clinical activities.
Negative Free Cash FlowPersistent negative free cash flow means operations do not self-fund strategic activities. Even with improved burn, ongoing FCF deficits necessitate capital raises or partner funding, raising dilution risk and constraining sustained investment in clinical development.
Eroded Asset And Equity BaseA sharp contraction in assets and equity reduces the financial cushion to absorb setbacks and limits balance-sheet capacity for strategic initiatives. Over months this erosion heightens dependence on external capital and increases vulnerability to dilution or restrictive financing terms.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $8.77M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,641 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Operating as a clinical-stage biopharmaceutical enterprise, Synlogic, Inc. is dedicated to the creation and progression of synthetic biotic therapeutics aimed at addressing metabolic and immunological conditions across the United States. Its robust portfolio features multiple drug candidates: SYNB1618 and SYNB1934, both non-systemically absorbed and orally administered, are progressing through Phase II clinical trials for phenylketonuria. Another oral, non-systemic agent, SYNB1353, is designed to treat homocystinuria. Furthermore, SYNB8802, an orally taken, non-systemic compound, is currently in Phase I trials for managing enteric hyperoxaluria. Beyond oral treatments, the company is also developing SYNB1891, an intratumorally delivered synthetic biotic medicine undergoing Phase I investigation for solid tumors and lymphoma. Synlogic, Inc. has established partnerships with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., and its main office is located in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.11% Insiders
0.04% Mutual Funds
0.20% Other Institutional Investors
99.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---